Biomarker Testing Services Market Size, Share & Trends Analysis Report By Services (Biomarker Assay Development & Validation, Flow Cytometry), By End-user (Research Institutes, CROS), By Region, And Segment Forecasts, 2022 - 2030
This report can be delivered to the clients within 3 Business Days
Biomarker Testing Services Market Growth & Trends
The global biomarker testing services market size is expected to reach USD 1,399.4 million by 2030, registering a CAGR of 6.9% during the forecast period, according to a new report by Grand View Research, Inc. Growing investment in pharmaceutical R&D, increasing demand for the precision medicine used for cancer treatment, and growing burden of the infectious and chronic diseases facilitating the demand for the biomarker testing are some of the major factors driving the market's growth.
There has been a consistent rise in clinical trials during the last 5 years. For instance, according to ClinicalTrials.gov, more than 262,298 trials were registered in 2018, whereas as of September 2022, above 399,518 trials were registered. Clinical trials are expected to improve in the coming years owing to the increase in funding for clinical research. This is expected to boost demand for medicine discovery research activities and thus support demand for biomarker testing in the post-pandemic period.
The FDA approval rate for medicines through the use of biomarkers has improved, over the years. For instance, in 2016, more than 26 trials were approved by the FDA that used biomarkers for medicine testing, whereas, in 2019, 36 trials were approved by the FDA that used biomarkers for medical testing. Clinical trials now require biomarker-related data for medicine approvals, as it provides information about the action of medicine in the body and thus speeds up the medicine approval process. This is expected to improve demand for biomarker testing during the forecast period.
Various biopharmaceutical companies are taking initiatives to improve the diagnosis rate of the cancer patient through biomarker testing. For instance, in April 2021, a biopharmaceutical company, Amgen launched the Biomarker Assist Program. As per this program, patients with metastatic (stage IV) non-small cell lung cancer (NSCLC) were provided biomarker testing, to check the presence of oncogene biomarkers, which help in targeted therapies. Such initiatives by the market players are likely to support the market's growth.
According to the IQVIA, report on oncology trends, clinical trials for cancer have been increasing for the last 10 years. For instance, in 2011, 1,242 trials were registered for cancer, and as of 2021, 2,335 trials were registered for cancer. The number of clinical trials intended for cancer is expected to rise even further owing to the growing prevalence of the disease. There is an increasing demand for targeted therapies designed for cancer that use biomarkers for testing the efficacy of the drug in the research. Increased cancer research in the coming years is expected to boost demand for the biomarkers designed for cancer testing and thus support the market in the post-pandemic period.
Biomarker Testing Services Market Report Highlights
Biomarker Testing Services Market Growth & Trends
The global biomarker testing services market size is expected to reach USD 1,399.4 million by 2030, registering a CAGR of 6.9% during the forecast period, according to a new report by Grand View Research, Inc. Growing investment in pharmaceutical R&D, increasing demand for the precision medicine used for cancer treatment, and growing burden of the infectious and chronic diseases facilitating the demand for the biomarker testing are some of the major factors driving the market's growth.
There has been a consistent rise in clinical trials during the last 5 years. For instance, according to ClinicalTrials.gov, more than 262,298 trials were registered in 2018, whereas as of September 2022, above 399,518 trials were registered. Clinical trials are expected to improve in the coming years owing to the increase in funding for clinical research. This is expected to boost demand for medicine discovery research activities and thus support demand for biomarker testing in the post-pandemic period.
The FDA approval rate for medicines through the use of biomarkers has improved, over the years. For instance, in 2016, more than 26 trials were approved by the FDA that used biomarkers for medicine testing, whereas, in 2019, 36 trials were approved by the FDA that used biomarkers for medical testing. Clinical trials now require biomarker-related data for medicine approvals, as it provides information about the action of medicine in the body and thus speeds up the medicine approval process. This is expected to improve demand for biomarker testing during the forecast period.
Various biopharmaceutical companies are taking initiatives to improve the diagnosis rate of the cancer patient through biomarker testing. For instance, in April 2021, a biopharmaceutical company, Amgen launched the Biomarker Assist Program. As per this program, patients with metastatic (stage IV) non-small cell lung cancer (NSCLC) were provided biomarker testing, to check the presence of oncogene biomarkers, which help in targeted therapies. Such initiatives by the market players are likely to support the market's growth.
According to the IQVIA, report on oncology trends, clinical trials for cancer have been increasing for the last 10 years. For instance, in 2011, 1,242 trials were registered for cancer, and as of 2021, 2,335 trials were registered for cancer. The number of clinical trials intended for cancer is expected to rise even further owing to the growing prevalence of the disease. There is an increasing demand for targeted therapies designed for cancer that use biomarkers for testing the efficacy of the drug in the research. Increased cancer research in the coming years is expected to boost demand for the biomarkers designed for cancer testing and thus support the market in the post-pandemic period.
Biomarker Testing Services Market Report Highlights
- The biomarker assay development & validation segment by service was expected to hold the largest share of 59.8% in 2021. Growing demand for companion diagnostics in the diagnosis of diseases is expected to support demand for the biomarker assay development & validation service
- Based on end-user, the pharmaceutical and biotechnology companies accounted for the largest share of 44.0% in 2021, owing to the rising investment in R&D by these companies
- North America held the largest share of 46.2% in 2021, The technologically advanced infrastructure for research and the increase in research investment by public organizations are supporting the regional market growth
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.1.1. Services
1.1.2. End-user
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.6.2. Volume price analysis (Model 2)
1.6.2.1. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective
1.9.2. Objective
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
CHAPTER 3. BIOMARKER TESTING SERVICES MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.1.1. Increasing demand for biomarker testing for cancer detection
3.3.1.2. Increasing R&D activities
3.3.1.3. Growing burden of chronic and infectious diseases supporting demand for biomarker testing
3.3.2. Market restraint analysis
3.3.2.1. High capital investments and lengthy timelines for biomarker development
3.4. Biomarker Testing Services Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.2. PESTEL Analysis
3.4.3. Major Deals & Strategic Alliances Analysis
3.4.3.1. Mergers and Acquisition
3.4.3.2. Expansions
3.4.3.3. Agreements and Collaborations
3.4.3.4. Product and Service Launches
3.5. Covid-19 Impact and Reformation Strategy
CHAPTER 4. BIOMARKER TESTING SERVICES MARKET: PRODUCT ESTIMATES & TREND ANALYSIS
4.1. Definitions and Scope
4.2. Biomarker Testing Services Market Share, 2021 & 2030
4.2.1. Biomarker Assay Development & Validation
4.2.1.1. Biomarker assay development & validation market estimates and forecast 2018 to 2030 (USD Billion)
4.2.2. Flow cytometry
4.2.2.1. Flow cytometry market estimates and forecast 2018 to 2030 (USD Billion)
4.2.3. Others
4.2.3.1. Others market estimates and forecast 2018 to 2030 (USD Billion)
CHAPTER 5. BIOMARKER TESTING SERVICES MARKET: END-USER ESTIMATES & TREND ANALYSIS
5.1. Definitions and Scope
5.2. Biomarker Testing Services Market Share, 2021 & 2030
5.2.1. Pharmaceutical and biotechnology companies
5.2.1.1. Pharmaceutical and biotechnology companies market estimates and forecast 2018 to 2030 (USD Billion)
5.2.2. Research Institutes
5.2.2.1. Research Institutes market estimates and forecast 2018 to 2030 (USD Billion)
5.2.3. CROS
5.2.3.1. CROS market estimates and forecast 2018 to 2030 (USD Billion)
CHAPTER 6. BIOMARKER TESTING SERVICES MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
6.1. Regional market share analysis, 2021& 2030
6.2. North America
6.2.1. U.S.
6.2.1.1. U.S. Market estimates and forecast, 2018 - 2030
6.2.2. Canada
6.2.2.1. Canada Market estimates and forecast, 2018 - 2030
6.3. Europe
6.3.1. U.K.
6.3.1.1. U.K. Market estimates and forecast, 2018 - 2030
6.3.2. Germany
6.3.2.1. Germany Market estimates and forecast, 2018 - 2030
6.3.3. France
6.3.3.1. France Market estimates and forecast, 2018 - 2030
6.3.4. Italy
6.3.4.1. Italy Market estimates and forecast, 2018 - 2030
6.3.5. Spain
6.3.5.1. Spain Market estimates and forecast, 2018 - 2030
6.3.6. Netherlands
6.3.6.1. Netherlands Market estimates and forecast, 2018 - 2030
6.3.7. Sweden
6.3.7.1. Sweden Market estimates and forecast, 2018 - 2030
6.3.8. Switzerland
6.3.8.1. Switzerland Market estimates and forecast, 2018 - 2030
6.4. Asia Pacific
6.4.1. Japan
6.4.1.1. Japan Market estimates and forecast, 2018 - 2030
6.4.2. China
6.4.2.1. China Market estimates and forecast, 2018 - 2030
6.4.3. India
6.4.3.1. India Market estimates and forecast, 2018 - 2030
6.4.4. Australia
6.4.4.1. Australia Market estimates and forecast, 2018 - 2030
6.4.5. South Korea
6.4.5.1. South Korea Market estimates and forecast, 2018 - 2030
6.4.6. Thailand
6.4.6.1. Thailand Market estimates and forecast, 2018 - 2030
6.4.7. Malaysia
6.4.7.1. Malaysia Market estimates and forecast, 2018 - 2030
6.4.8. Indonesia
6.4.8.1. New Zealand Market estimates and forecast, 2018 - 2030
6.4.9. Taiwan
6.4.9.1. Philippines Market estimates and forecast, 2018 - 2030
6.4.10. Singapore
6.4.10.1. Singapore Market estimates and forecast, 2018 - 2030
6.5. Latin America
6.5.1. Brazil
6.5.1.1. Brazil Market estimates and forecast, 2018 - 2030
6.5.2. Mexico
6.5.2.1. Mexico Market estimates and forecast, 2018 - 2030
6.5.3. Argentina
6.5.3.1. Argentina Market estimates and forecast, 2018 - 2030
6.5.4. Colombia;
6.5.4.1. Colombia Market estimates and forecast, 2018 - 2030
6.6. MEA
6.6.1. South Africa
6.6.1.1. South Africa Market estimates and forecast, 2018 - 2030
6.6.2. Saudi Arabia
6.6.2.1. Saudi Arabia Market estimates and forecast, 2018 - 2030
6.6.3. UAE
6.6.3.1. UAE Market estimates and forecast, 2018 - 2030
6.6.4. Israel
6.6.4.1. Israel Market estimates and forecast, 2018 - 2030
CHAPTER 7. COMPETITIVE ANALYSIS
7.1. Recent Developments & Impact Analysis, By Key Market Participant
7.2. Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
7.3. Participant Categorization
7.4. Vendor Landscape
7.4.1. List of Key Service Providers
7.4.2. Market Differentiators
7.4.3. Biomarker Testing Services Market Share Analysis
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Company Profiles
8.1.1. Bio Agilytix Labs
8.1.1.1. Company overview
8.1.1.2. Service Benchmarking
8.1.1.3. Strategic initiatives
8.1.2. Eurofins Scientific
8.1.2.1. Company overview
8.1.2.2. Financial performance
8.1.2.3. Service Benchmarking
8.1.2.4. Strategic initiatives
8.1.3. SGS SA
8.1.3.1. Company overview
8.1.3.2. Financial performance
8.1.3.3. Service Benchmarking
8.1.3.4. Strategic initiatives
8.1.4. Charles River Laboratories
8.1.4.1. Company overview
8.1.4.2. Financial performance
8.1.4.3. Service Benchmarking
8.1.4.4. Strategic initiatives
8.1.5. Laboratory Corporation of America Holding
8.1.5.1. Company overview
8.1.5.2. Financial performance
8.1.5.3. Service Benchmarking
8.1.5.4. Strategic initiatives
8.1.6. Thermo Fisher Scientific, Inc. (PPD, Inc.)
8.1.6.1. Company overview
8.1.6.2. Financial performance
8.1.6.3. Service Benchmarking
8.1.6.4. Strategic initiatives
8.1.7. ICON Plc
8.1.7.1. Company overview
8.1.7.2. Financial performance
8.1.7.3. Service Benchmarking
8.1.7.4. Strategic initiatives
8.1.8. IQVIA, Inc.
8.1.8.1. Company overview
8.1.8.2. Financial performance
8.1.8.3. Service Benchmarking
8.1.8.4. Strategic initiatives
8.1.9. Syneos Health
8.1.9.1. Company overview
8.1.9.2. Financial performance
8.1.9.3. Service Benchmarking
8.1.9.4. Strategic initiatives
8.1.10. Intertek Group Plc
8.1.10.1. Company overview
8.1.10.2. Financial performance
8.1.10.3. Service Benchmarking
8.1.10.4. Strategic initiatives
1.1. Market Segmentation & Scope
1.1.1. Services
1.1.2. End-user
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.6.2. Volume price analysis (Model 2)
1.6.2.1. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective
1.9.2. Objective
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
CHAPTER 3. BIOMARKER TESTING SERVICES MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.1.1. Increasing demand for biomarker testing for cancer detection
3.3.1.2. Increasing R&D activities
3.3.1.3. Growing burden of chronic and infectious diseases supporting demand for biomarker testing
3.3.2. Market restraint analysis
3.3.2.1. High capital investments and lengthy timelines for biomarker development
3.4. Biomarker Testing Services Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.2. PESTEL Analysis
3.4.3. Major Deals & Strategic Alliances Analysis
3.4.3.1. Mergers and Acquisition
3.4.3.2. Expansions
3.4.3.3. Agreements and Collaborations
3.4.3.4. Product and Service Launches
3.5. Covid-19 Impact and Reformation Strategy
CHAPTER 4. BIOMARKER TESTING SERVICES MARKET: PRODUCT ESTIMATES & TREND ANALYSIS
4.1. Definitions and Scope
4.2. Biomarker Testing Services Market Share, 2021 & 2030
4.2.1. Biomarker Assay Development & Validation
4.2.1.1. Biomarker assay development & validation market estimates and forecast 2018 to 2030 (USD Billion)
4.2.2. Flow cytometry
4.2.2.1. Flow cytometry market estimates and forecast 2018 to 2030 (USD Billion)
4.2.3. Others
4.2.3.1. Others market estimates and forecast 2018 to 2030 (USD Billion)
CHAPTER 5. BIOMARKER TESTING SERVICES MARKET: END-USER ESTIMATES & TREND ANALYSIS
5.1. Definitions and Scope
5.2. Biomarker Testing Services Market Share, 2021 & 2030
5.2.1. Pharmaceutical and biotechnology companies
5.2.1.1. Pharmaceutical and biotechnology companies market estimates and forecast 2018 to 2030 (USD Billion)
5.2.2. Research Institutes
5.2.2.1. Research Institutes market estimates and forecast 2018 to 2030 (USD Billion)
5.2.3. CROS
5.2.3.1. CROS market estimates and forecast 2018 to 2030 (USD Billion)
CHAPTER 6. BIOMARKER TESTING SERVICES MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
6.1. Regional market share analysis, 2021& 2030
6.2. North America
6.2.1. U.S.
6.2.1.1. U.S. Market estimates and forecast, 2018 - 2030
6.2.2. Canada
6.2.2.1. Canada Market estimates and forecast, 2018 - 2030
6.3. Europe
6.3.1. U.K.
6.3.1.1. U.K. Market estimates and forecast, 2018 - 2030
6.3.2. Germany
6.3.2.1. Germany Market estimates and forecast, 2018 - 2030
6.3.3. France
6.3.3.1. France Market estimates and forecast, 2018 - 2030
6.3.4. Italy
6.3.4.1. Italy Market estimates and forecast, 2018 - 2030
6.3.5. Spain
6.3.5.1. Spain Market estimates and forecast, 2018 - 2030
6.3.6. Netherlands
6.3.6.1. Netherlands Market estimates and forecast, 2018 - 2030
6.3.7. Sweden
6.3.7.1. Sweden Market estimates and forecast, 2018 - 2030
6.3.8. Switzerland
6.3.8.1. Switzerland Market estimates and forecast, 2018 - 2030
6.4. Asia Pacific
6.4.1. Japan
6.4.1.1. Japan Market estimates and forecast, 2018 - 2030
6.4.2. China
6.4.2.1. China Market estimates and forecast, 2018 - 2030
6.4.3. India
6.4.3.1. India Market estimates and forecast, 2018 - 2030
6.4.4. Australia
6.4.4.1. Australia Market estimates and forecast, 2018 - 2030
6.4.5. South Korea
6.4.5.1. South Korea Market estimates and forecast, 2018 - 2030
6.4.6. Thailand
6.4.6.1. Thailand Market estimates and forecast, 2018 - 2030
6.4.7. Malaysia
6.4.7.1. Malaysia Market estimates and forecast, 2018 - 2030
6.4.8. Indonesia
6.4.8.1. New Zealand Market estimates and forecast, 2018 - 2030
6.4.9. Taiwan
6.4.9.1. Philippines Market estimates and forecast, 2018 - 2030
6.4.10. Singapore
6.4.10.1. Singapore Market estimates and forecast, 2018 - 2030
6.5. Latin America
6.5.1. Brazil
6.5.1.1. Brazil Market estimates and forecast, 2018 - 2030
6.5.2. Mexico
6.5.2.1. Mexico Market estimates and forecast, 2018 - 2030
6.5.3. Argentina
6.5.3.1. Argentina Market estimates and forecast, 2018 - 2030
6.5.4. Colombia;
6.5.4.1. Colombia Market estimates and forecast, 2018 - 2030
6.6. MEA
6.6.1. South Africa
6.6.1.1. South Africa Market estimates and forecast, 2018 - 2030
6.6.2. Saudi Arabia
6.6.2.1. Saudi Arabia Market estimates and forecast, 2018 - 2030
6.6.3. UAE
6.6.3.1. UAE Market estimates and forecast, 2018 - 2030
6.6.4. Israel
6.6.4.1. Israel Market estimates and forecast, 2018 - 2030
CHAPTER 7. COMPETITIVE ANALYSIS
7.1. Recent Developments & Impact Analysis, By Key Market Participant
7.2. Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
7.3. Participant Categorization
7.4. Vendor Landscape
7.4.1. List of Key Service Providers
7.4.2. Market Differentiators
7.4.3. Biomarker Testing Services Market Share Analysis
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Company Profiles
8.1.1. Bio Agilytix Labs
8.1.1.1. Company overview
8.1.1.2. Service Benchmarking
8.1.1.3. Strategic initiatives
8.1.2. Eurofins Scientific
8.1.2.1. Company overview
8.1.2.2. Financial performance
8.1.2.3. Service Benchmarking
8.1.2.4. Strategic initiatives
8.1.3. SGS SA
8.1.3.1. Company overview
8.1.3.2. Financial performance
8.1.3.3. Service Benchmarking
8.1.3.4. Strategic initiatives
8.1.4. Charles River Laboratories
8.1.4.1. Company overview
8.1.4.2. Financial performance
8.1.4.3. Service Benchmarking
8.1.4.4. Strategic initiatives
8.1.5. Laboratory Corporation of America Holding
8.1.5.1. Company overview
8.1.5.2. Financial performance
8.1.5.3. Service Benchmarking
8.1.5.4. Strategic initiatives
8.1.6. Thermo Fisher Scientific, Inc. (PPD, Inc.)
8.1.6.1. Company overview
8.1.6.2. Financial performance
8.1.6.3. Service Benchmarking
8.1.6.4. Strategic initiatives
8.1.7. ICON Plc
8.1.7.1. Company overview
8.1.7.2. Financial performance
8.1.7.3. Service Benchmarking
8.1.7.4. Strategic initiatives
8.1.8. IQVIA, Inc.
8.1.8.1. Company overview
8.1.8.2. Financial performance
8.1.8.3. Service Benchmarking
8.1.8.4. Strategic initiatives
8.1.9. Syneos Health
8.1.9.1. Company overview
8.1.9.2. Financial performance
8.1.9.3. Service Benchmarking
8.1.9.4. Strategic initiatives
8.1.10. Intertek Group Plc
8.1.10.1. Company overview
8.1.10.2. Financial performance
8.1.10.3. Service Benchmarking
8.1.10.4. Strategic initiatives
LIST OF TABLES
Table 1 List of secondary sources
Table 2 List of Abbreviations
Table 1 List of secondary sources
Table 2 List of Abbreviations
LIST OF FIGURES
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value - chain - based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Commodity flow analysis
Fig. 9 Volume Price Analysis
Fig. 10 Biomarker Testing Services market snapshot (2021)
Fig. 11 Biomarker Testing Services market segmentation
Fig. 12 Market driver relevance analysis (Current & future impact)
Fig. 13 Market restraint relevance analysis (Current & future impact)
Fig. 14 Penetration & growth prospect mapping
Fig. 15 Porter’s five forces analysis
Fig. 16 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 17 Biomarker Testing Services market service outlook: Segment dashboard
Fig. 18 Biomarker Testing Services market: Service movement analysis
Fig. 19 Biomarker Assay Development & Validation market (USD Million)
Fig. 20 Flow cytometry market (USD Million)
Fig. 21 Others market (USD Million)
Fig. 22 Biomarker Testing Services market End - user outlook: Segment dashboard
Fig. 23 Biomarker Testing Services market: End - user movement analysis
Fig. 24 Pharmaceutical and biotechnology companies market (USD Million)
Fig. 25 Research Institutes market (USD Million)
Fig. 26 CROs market (USD Million)
Fig. 27 Regional market: Key takeaways
Fig. 28 Regional outlook, 2021 & 2030
Fig. 29 North America market, 2018 - 2030 (USD Million)
Fig. 30 U.S. market, 2018 - 2030 (USD Million)
Fig. 31 Canada Market, 2018 - 2030 (USD Million)
Fig. 32 Europe Market, 2018 - 2030 (USD Million)
Fig. 33 U.K Market, 2018 - 2030 (USD Million)
Fig. 34 Germany Market, 2018 - 2030 (USD Million)
Fig. 35 France Market, 2018 - 2030 (USD Million)
Fig. 36 Italy Market, 2018 - 2030 (USD Million)
Fig. 37 Spain Market, 2018 - 2030 (USD Million)
Fig. 38 Netherlands Market, 2018 - 2030 (USD Million)
Fig. 39 Switzerland Market, 2018 - 2030 (USD Million)
Fig. 40 Sweden Market, By Service, 2018 - 2030 (USD Million)
Fig. 41 Asia Pacific market, 2018 - 2030 (USD Million)
Fig. 42 China market, 2018 - 2030 (USD Million)
Fig. 43 India market, 2018 - 2030 (USD Million)
Fig. 44 Japan market, 2018 - 2030 (USD Million)
Fig. 45 Australia market, 2018 - 2030 (USD Million)
Fig. 46 Malaysia market, 2018 - 2030 (USD Million)
Fig. 47 Indonesia market, 2018 - 2030 (USD Million)
Fig. 48 Taiwan market, 2018 - 2030 (USD Million)
Fig. 49 Thailand market, 2018 - 2030 (USD Million)
Fig. 50 Singapore market, 2018 - 2030 (USD Million)
Fig. 51 South Korea market, 2018 - 2030 (USD Million)
Fig. 52 Latin America market, 2018 - 2030 (USD Million)
Fig. 53 Brazil market, 2018 - 2030 (USD Million)
Fig. 54 Mexico market, 2018 - 2030 (USD Million)
Fig. 55 Argentina market, 2018 - 2030 (USD Million)
Fig. 56 Colombia market, 2018 - 2030 (USD Million)
Fig. 57 MEA market, 2018 - 2030 (USD Million)
Fig. 58 South Africa market, 2018 - 2030 (USD Million)
Fig. 59 Saudi Arabia market, 2018 - 2030 (USD Million)
Fig. 60 Israel market, 2018 - 2030 (USD Million)
Fig. 61 UAE market, 2018 - 2030 (USD Million)
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value - chain - based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Commodity flow analysis
Fig. 9 Volume Price Analysis
Fig. 10 Biomarker Testing Services market snapshot (2021)
Fig. 11 Biomarker Testing Services market segmentation
Fig. 12 Market driver relevance analysis (Current & future impact)
Fig. 13 Market restraint relevance analysis (Current & future impact)
Fig. 14 Penetration & growth prospect mapping
Fig. 15 Porter’s five forces analysis
Fig. 16 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 17 Biomarker Testing Services market service outlook: Segment dashboard
Fig. 18 Biomarker Testing Services market: Service movement analysis
Fig. 19 Biomarker Assay Development & Validation market (USD Million)
Fig. 20 Flow cytometry market (USD Million)
Fig. 21 Others market (USD Million)
Fig. 22 Biomarker Testing Services market End - user outlook: Segment dashboard
Fig. 23 Biomarker Testing Services market: End - user movement analysis
Fig. 24 Pharmaceutical and biotechnology companies market (USD Million)
Fig. 25 Research Institutes market (USD Million)
Fig. 26 CROs market (USD Million)
Fig. 27 Regional market: Key takeaways
Fig. 28 Regional outlook, 2021 & 2030
Fig. 29 North America market, 2018 - 2030 (USD Million)
Fig. 30 U.S. market, 2018 - 2030 (USD Million)
Fig. 31 Canada Market, 2018 - 2030 (USD Million)
Fig. 32 Europe Market, 2018 - 2030 (USD Million)
Fig. 33 U.K Market, 2018 - 2030 (USD Million)
Fig. 34 Germany Market, 2018 - 2030 (USD Million)
Fig. 35 France Market, 2018 - 2030 (USD Million)
Fig. 36 Italy Market, 2018 - 2030 (USD Million)
Fig. 37 Spain Market, 2018 - 2030 (USD Million)
Fig. 38 Netherlands Market, 2018 - 2030 (USD Million)
Fig. 39 Switzerland Market, 2018 - 2030 (USD Million)
Fig. 40 Sweden Market, By Service, 2018 - 2030 (USD Million)
Fig. 41 Asia Pacific market, 2018 - 2030 (USD Million)
Fig. 42 China market, 2018 - 2030 (USD Million)
Fig. 43 India market, 2018 - 2030 (USD Million)
Fig. 44 Japan market, 2018 - 2030 (USD Million)
Fig. 45 Australia market, 2018 - 2030 (USD Million)
Fig. 46 Malaysia market, 2018 - 2030 (USD Million)
Fig. 47 Indonesia market, 2018 - 2030 (USD Million)
Fig. 48 Taiwan market, 2018 - 2030 (USD Million)
Fig. 49 Thailand market, 2018 - 2030 (USD Million)
Fig. 50 Singapore market, 2018 - 2030 (USD Million)
Fig. 51 South Korea market, 2018 - 2030 (USD Million)
Fig. 52 Latin America market, 2018 - 2030 (USD Million)
Fig. 53 Brazil market, 2018 - 2030 (USD Million)
Fig. 54 Mexico market, 2018 - 2030 (USD Million)
Fig. 55 Argentina market, 2018 - 2030 (USD Million)
Fig. 56 Colombia market, 2018 - 2030 (USD Million)
Fig. 57 MEA market, 2018 - 2030 (USD Million)
Fig. 58 South Africa market, 2018 - 2030 (USD Million)
Fig. 59 Saudi Arabia market, 2018 - 2030 (USD Million)
Fig. 60 Israel market, 2018 - 2030 (USD Million)
Fig. 61 UAE market, 2018 - 2030 (USD Million)
